期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 58, 期 2, 页码 916-922出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02020-13
关键词
-
资金
- Astellas
- Basilea
- Merck
- Gilead
- Pfizer
Since epidemiological cutoff values (ECVs) using CLSI MICs from multiple laboratories are not available for Candida spp. and the echinocandins, we established ECVs for anidulafungin and micafungin on the basis of wild-type (WT) MIC distributions (for organisms in a species-drug combination with no detectable acquired resistance mechanisms) for 8,210 Candida albicans, 3,102 C. glabrata, 3,976 C. parapsilosis, 2,042 C. tropicalis, 617 C. krusei, 258 C. lusitaniae, 234 C. guilliermondii, and 131 C. dubliniensis isolates. CLSI broth microdilution MIC data gathered from 15 different laboratories in Canada, Europe, Mexico, Peru, and the United States were aggregated to statistically define ECVs. ECVs encompassing 97.5% of the statistically modeled population for anidulafungin and micafungin were, respectively, 0.12 and 0.03 mu g/ml for C. albicans, 0.12 and 0.03 mu g/ml for C. glabrata, 8 and 4 mu g/ml for C. parapsilosis, 0.12 and 0.06 mu g/ml for C. tropicalis, 0.25 and 0.25 mu g/ml for C. krusei, 1 and 0.5 mu g/ml for C. lusitaniae, 8 and 2 mu g/ml for C. guilliermondii, and 0.12 and 0.12 mu g/ml for C. dubliniensis. Previously reported single and multicenter ECVs defined in the present study were quite similar or within 1 2-fold dilution of each other. For a collection of 230 WT isolates (no fks mutations) and 51 isolates with fks mutations, the species-specific ECVs for anidulafungin and micafungin correctly classified 47 (92.2%) and 51 (100%) of the fks mutants, respectively, as non-WT strains. These ECVs may aid in detecting non-WT isolates with reduced susceptibility to anidulafungin and micafungin due to fks mutations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据